

INTERNATIONAL CONGRESS  
**MULTIPLE MYELOMA**  
and related malignancies



■ 6<sup>th</sup> Edition

**HYBRID**

**Presidents**

Prof. Angelo Vacca

Prof. Roberto Ria

**BARI (ITALY)**

November 3-5, 2022

Villa Romanazzi Carducci

Under the auspices of:



UNIVERSITÀ  
DEGLI STUDI DI BARI  
ALDO MORO

## **SIE - Società Italiana di Ematologia**



— SIMI —  
SOCIETÀ ITALIANA  
DI MEDICINA INTERNA  
*Patrocinio*



## **SCIENTIFIC SECRETARIAT**

**Sebastiano Cicco**

**Vanessa De Santis**

**Antonio Gnoni**

**Aurelia Lamanuzzi**

**Ilaria Saltarella**

**Antonio Giovanni Solimando**

## PRESENTATION

In the last 15 to 20 years remarkable advancements in the understanding of the pathophysiology of multiple myeloma and related malignancies have paved the way to the identification and the subsequent adoption of new effective and safe therapies. Thus, following the 5<sup>th</sup> edition which was held on November 5-7<sup>th</sup>, 2020, the time has come for a thorough biological and clinical update. Like in the previous editions, our aim is to provide hematologists, oncologists, internists, radiologists, and other medical specialists as well as young researchers, residents, doctoral and undergraduate students with an invaluable opportunity to deepen and update their knowledge on the already acquired and emerging developments in the biology and management of multiple myeloma and related malignancies.

A number of internationally renowned speakers have been invited to deliver state-of-the-art lectures on cutting edge topics. These will include genetic and epigenetic features of myeloma biology, molecular and biological mechanisms of disease progression, new prognostic markers and novel approaches to assess the response to therapy, new single or combined therapeutic molecules specifically targeting tumor cells and/or their microenvironment. Autologous and allogeneic stem cell transplantation, bispecific monoclonal antibodies, and CAR-T cells will also be the object of intensive scrutiny. Finally, supportive therapy, emerging toxicity, and infectious complications will be discussed in their many facets.

We are confident that at the end of the meeting all of us will be enriched with fresh stimuli and renewed enthusiasm, with the deep awareness that the enduring challenges posed by multiple myeloma and cognate tumors may now be approached with more rational and more effective achievements.

**Angelo Vacca, Roberto Ria**

## FACULTY

<b>Bavaro Davide</b>	BARI (IT)	<b>Mateos Maria-Victoria</b>	SALAMANCA (ES)
<b>Beksac Meral</b>	ANKARA (TR)	<b>Mercadante Sebastiano</b>	PALERMO (IT)
<b>Belmatoug Nadia</b>	CLICHY (FR)	<b>Milani Paolo</b>	PAVIA (IT)
<b>Boccardo Mario</b>	TURIN (IT)	<b>Montefusco Vittorio</b>	MILAN (IT)
<b>Bolli Niccolò</b>	MILAN (IT)	<b>Musto Pellegrino</b>	BARI (IT)
<b>Bruno Benedetto</b>	TURIN (IT)	<b>Neparidze Natalia</b>	NEW HAVEN (USA)
<b>Castillo Jorge J</b>	BOSTON (USA)	<b>Patriarca Francesca</b>	UDINE (IT)
<b>Cavo Michele</b>	BOLOGNA (IT)	<b>Petrucci Maria Teresa</b>	ROME (IT)
<b>Cerchione Claudio</b>	MELDOLA (IT)	<b>Popat Rakesh</b>	LONDON (UK)
<b>Cook Gordon</b>	LEEDS (UK)	<b>Quinti Isabella</b>	ROME (IT)
<b>Corso Alessandro</b>	LEGNANO (IT)	<b>Reale Annie</b>	MELBOURNE (AU)
<b>Dammacco Franco</b>	BARI (IT)	<b>Ria Roberto</b>	BARI (IT)
<b>Delgado-Calle Jesus</b>	LITTLE ROCK (USA)	<b>Roccaro Aldo M.</b>	BRESCIA (IT)
<b>Derudas Daniele</b>	CAGLIARI (IT)	<b>Sachpekidis Christos</b>	HEIDELBERG (DE)
<b>Di Ianni Mauro</b>	PESCARA (IT)	<b>Saracino Annalisa</b>	BARI (IT)
<b>Di Raimondo Francesco</b>	CATANIA (IT)	<b>Solimando Antonio Giovanni</b>	BARI (IT)
<b>Edgar David</b>	DUBLIN (IRL)	<b>Sonneveld Pieter</b>	ROTTERDAM (NL)
<b>Einsele Hermann</b>	WÜRZBURG (DE)	<b>Spencer Andrew</b>	MELBOURNE (AU)
<b>Gay Francesca</b>	TURIN (IT)	<b>Terragna Carolina</b>	BOLOGNA (IT)
<b>Gentile Massimo</b>	COSENZA (IT)	<b>Vacca Angelo</b>	BARI (IT)
<b>Giuliani Nicola</b>	PARMA (IT)	<b>Vanderkerken Karin</b>	BRUSSELS (BE)
<b>Hájek Roman</b>	OSTRAVA (CZ)	<b>Willenbacher Ella</b>	INNSBRUCK (AT)
<b>Humblet-Baron Stephanie</b>	LEUVEN (BE)	<b>Willenbacher Wolfgang</b>	INNSBRUCK (AT)
<b>Massaia Massimo</b>	CUNEO (IT)		

# PROGRAMME - Thursday, November 3, 2022

13.30 – 14.15 Registration of participants

14.15 – 14.30 Welcome speech and orientation  
**Angelo Vacca, Roberto Ria**

14.30 – 15.15 Overture Lecture  
**Chairperson: Angelo Vacca**

Role of immunotherapy in Multiple Myeloma  
**Michele Cavo**

## **15.15 – 17.25 Workshop 1 Biology, Bone Disease, and Immunodeficiency in Multiple Myeloma** **Chairpersons: Andrew Spencer, Karin Vanderkerken**

15.15 – 15.35 Epigenetic architecture in multiple myeloma  
**Aldo M. Roccaro**

15.35 – 15.55 What's new about transcription factors in multiple myeloma  
**Andrew Spencer**

15.55 – 16.15 Myeloid-derived suppressor cells as inducers of immunosuppression  
**Karin Vanderkerken**

16.15 – 16.35 Notch3 signaling between myeloma cells and osteocytes  
**Jesus Delgado-Calle**

16.35 – 17.05 Keynote Lecture  
**Chairperson: Franco Dammacco**  
Bispecific antibodies: new developments  
**Hermann Einsele**

17.05 – 17.25 Molecular pathways governing the pathogenesis of myeloma bone disease  
**Nicola Giuliani**

17.25 – 17.45 *Coffee break*

## **17.45 – 18.15 Hot Topic: Covid-19 pandemic and Plasma Cell Dyscrasias** **Chairpersons: Stéphanie Humblet-Baron, Ella Willenbacher**

17.45 – 18.00 Changed approaches and follow-ups of myeloma patients in the COVID-19 era  
**Natalia Neparidze**

18.00 – 18.15 Are COVID-19 vaccines effective, and should all myeloma patients receive a vaccine?  
**Stephanie Humblet-Baron**

18.15 – 19.15 Poster Round and Discussion (non-curricular activity)  
**Chairpersons: Nicola Giuliani, Aldo M. Roccaro**

## 08.30 – 10.30 Workshop 2

### Diagnosis, Prognosis and Clinical Features

Chairpersons: **Wolfgang Willenbacher, Niccolò Bolli**

- 08.30 – 08.50 Functional impact of genomic complexity of the transcriptome of multiple myeloma  
**Niccolò Bolli**
- 08.50 – 09.10 Monoclonal gammopathies of renal significance  
**Daniele Derudas**
- 09.10 – 09.30 Personalized therapy for pain management in multiple myeloma  
**Sebastiano Mercadante**
- 09.30 – 09.50 Circulating tumor cells and homing to check myeloma progression  
**Antonio Giovanni Solimando**
- 09.50 – 10.10 Positron emission tomography (PET) in multiple myeloma  
**Christos Sachpekidis**
- 10.10 – 10.30 Collection data of myeloma patients to increase knowledge and improve management  
**Wolfgang Willenbacher**
- 10.30 – 10.50 *Coffee break*

## 10.50 – 13.10 Workshop 3

### First Line Therapy

Chairpersons: **Mario Boccardo, Pieter Sonneveld**

- 10.50 – 11.10 Frontline therapy for newly diagnosed young patients  
**Mario Boccardo**
- 11.10 – 11.30 New approaches to induction therapy  
**Francesca Patriarca**
- 11.30 – 11.50 Latest evidence on consolidation and maintenance  
**Pieter Sonneveld**
- 11.50 – 12.10 Upfront therapy in not transplantable patients  
**Francesca Gay**
- 12.10 – 12.30 Newly diagnosed elderly and very elderly myeloma patients  
**Gordon Cook**
- 12.30 – 12.50 Next Generation Sequencing for minimal residual disease  
**Carolina Terragna**
- 12.50 – 13.10 miRNA and lncRNA of bone marrow microenvironment as support for myeloma plasma cells  
**Angelo Vacca**
- 13.10 – 15.00 *Lunch*

**15.00 – 15.45 Hot Topic: Novel approaches to prophylaxis and management of infections in patients with multiple myeloma**

**Chairpersons: Isabella Quinti, Annalisa Saracino**

15.00 – 15.15 The immunosuppressive microenvironment of multiple myeloma

**Massimo Massaia**

15.15 – 15.30 Frequent soft tissue infections in myeloma patients and new antibiotic therapy

**Davide Bavaro**

15.30 – 15.45 Indication and management of Immunoglobulin replacement therapy in myeloma patients

**David Edgar**

15.45 – 16.00 *Coffee break*

**16.00 – 18.40 Workshop 4**

**Relapsed/Refractory Myeloma and the Newest Drugs**

**Chairpersons: María-Victoria Mateos, Alessandro Corso**

16.00 – 16.20 The choice of therapy at first relapse

**Alessandro Corso**

16.20 – 16.40 Over the second relapse

**Maria Teresa Petrucci**

16.40 – 17.00 How I treat refractory patients

**María-Victoria Mateos**

17.00 – 17.20 RWE: modern triplets in RRMM

**Roman Hájek**

17.20 – 17.40 Emerging therapeutic target in multiple myeloma

**Annie Reale**

17.40 – 18.00 CELMoDs as a new drug class for Multiple Myeloma therapy

**Roberto Ria**

18.00 – 18.20 New schema with anti-SLAMF7 for relapsed/refractory patients

**Massimo Gentile**

18.20 – 18.40 Second generation anti-CD38 MAb

**Vittorio Montefusco**

20.30 *Dinner*

## PROGRAMME - Saturday, November 5, 2022

### 08.30 – 10.50 Workshop 5

#### Progression and Management of Multiple Myeloma and other Plasma Cell Dyscrasias

Chairpersons: **Francesco Di Raimondo, Jorge J. Castillo**

- 08.30 – 08.50 Clinical or biochemical progression of myeloma: when patients need new treatment  
**Francesco Di Raimondo**
- 08.50 – 09.10 Selinexor and belantamab mafodotin for the treatment of triple class refractory myeloma  
**Claudio Cerchione**
- 09.10 – 09.30 Extramedullary myeloma  
**Meral Beksac**
- 09.30 – 09.50 New therapeutic approaches to Waldenström's macroglobulinemia  
**Jorge J. Castillo**
- 09.50 – 10.10 Therapeutic advancements in AL amyloidosis  
**Paolo Milani**
- 10.10 – 10.30 Primary and secondary plasma cell leukemia: new definition and therapeutic advances  
**Pellegrino Musto**
- 10.30 – 10.50 Gaucher disease: a rare condition associated to monoclonal gammopathies  
**Nadia Belmatoug**
- 10.50 – 11.10 *Coffee break*

### 11.10 – 12.10 Hot Topic: CAR-T cells: an Enticing Approach in the Management of Multiple Myeloma

Chairpersons: **Benedetto Bruno, Pellegrino Musto**

- 11.10 – 11.30 Evolution of CAR-T cells  
**Mauro Di Ianni**
- 11.30 – 11.50 Efficacy of CAR-T therapy in multiple myeloma  
**Rakesh Popat**
- 11.50 – 12.10 Overcome resistance of CAR-T  
**Benedetto Bruno**
- 12.10 – 12.20 Closing Remarks  
**Angelo Vacca, Roberto Ria**
- 12.20 Congress closure and CME questionnaire



## In person

### VENUE

Villa Romanazzi Carducci  
Via G. Capruzzi 326 – Bari (ITALY)

### REGISTRATION

Attendance is free of charge.

Registration for in person and online participation can be made through the website [www.meeting-planner.it](http://www.meeting-planner.it) (select the congress in the section “Calendario eventi” - Eventi).

### CONTINUING MEDICAL EDUCATION (CME) - event n. 362868

This Congress has been assigned n. **9,8** credits.

This training event is for **200** attendees. Medical specialists in the following areas:

Internal Medicine, Allergology and Clinical Immunology, Hematology, Oncology, Infectious diseases, Radiology, Radiotherapy, Orthopedics and traumatology and Clinical Biochemistry.

Other healthcare professionals: Biologists and Nurses.

CME credits can be claimed and your CME certificate issued only if you:

- have attended the entire training event
- have passed the CME assessment survey (a score of 75% or higher must be attained)

There can be no exceptions to these mandatory steps.

Attendants are also required not to exceed acquiring over 1/3 of their credits for the three-year period (2020-2022) by recruitment invitation.

### AIMS OF THE TRAINING PROCESS

Guidelines, Protocols, Procedures (2)

### LANGUAGE

The official language is English.

Recommended devices: PC/LAPTOP/MAC

Browser: GOOGLE CHROME

## PROVIDER AND ORGANIZING SECRETARIAT



### MEETING PLANNER

National CME Provider for Italy, registered as no. 2516  
Via Divisione Paracadutisti Folgore, 5 - 70125 BARI (Italy)  
TEL. +39 080.9905360 • FAX +39 080.9905359 • +39 080.2140203  
Email: [info@meeting-planner.it](mailto:info@meeting-planner.it) - [www.meeting-planner.it](http://www.meeting-planner.it)

SISTEMA DI GESTIONE  
QUALITÀ CERTIFICATO



UNI EN ISO 9001:2015





With the unconditional support of:



A Menarini Group Company

